FDA denies approval to Actos successor

The Food and Drug Administration has denied approval to the successor of the type II diabetes drug Actos. The agency cited a need for additional data from the drug’s manufacturer, Takeda Pharmaceuticals, amid concerns about the possible side effects of the drug, known as alogliptin.